News
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease
February 26, 2014 | Press ReleaseGalectin Therapeutics Presents at JMP Securities’ Nonalcoholic Steatohepatitis (NASH) Workshop
February 24, 2014 | Press ReleaseGalectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
February 13, 2014 | Press ReleaseGalectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
February 5, 2014 | Press ReleaseHighlights
View a webcast featuring Galectin Therapeutics’ CEO presenting at 16th Annual BIO CEO & Investor Conference
February 10, 2014 | WebcastView the most recent Galectin Therapeutics Corporate Presentation
February 10, 2014 | Resource
Galectin Therapeutics, Inc.
NASDAQ: GALT
15.15-0.78Stock price updates every 30 minutes.